A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
This study is testing a new medication called TER-2013 to see how well it treats various advanced solid tumors, including breast, ovarian, and lung cancers. It specifically focuses on cancers with certain genetic changes in the AKT/PI3K/PTEN pathway, which are proteins that can cause cancer cells to grow uncontrollably.
You may be eligible if you have advanced cancer that has spread or cannot be removed by surgery and is no longer responding to standard treatments. You must also be physically active and have healthy organ function to safely take the medication.
Participants will receive the experimental drug TER-2013, sometimes in combination with a hormone-blocking medication called Fulvestrant. Throughout the study, doctors will closely monitor your health, how your body processes the medicine, and how your tumor responds to the treatment.
The study is currently recruiting patients at medical centers in Orlando, Boston, and Rochester. You can talk to your doctor to see if one of these locations is a good fit for you.
- 1The study tests a new experimental drug for cancers with specific genetic markers.
- 2Participants must be able to carry out normal daily activities.
- 3Your health and safety are monitored very closely by the research team throughout the process.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.